Avita Medical says UK case series supports RECELL GO use in burn surgery patients

Avita Medical

Avita Medical

RCEL

0.00

  • Avita Medical highlighted first U.K. clinical experience with its RECELL GO device, with results already presented at the 2026 British Burn Association meeting.
  • A case series of 17 burn and reconstructive surgery patients reported successful treatment with RECELL GO-prepared Spray-On Skin Cells, with no discharge complications.
  • Clinicians reported smoother operating room workflow, citing more consistent cell preparation with less procedural variability versus manual processing.
  • Management positioned the data as support for broader international rollout, with RECELL GO already CE-marked in Europe and the U.K. and authorized in Australia and New Zealand.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Avita Medical Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606180840PRIMZONEFULLFEED9748982) on June 18, 2026, and is solely responsible for the information contained therein.